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Abstract	
	The	 present	 report	 examines	 the	 impact	 of		 the	 current	 limitations	 of	 the	microcephaly	definition	 in	the	context	of	 the	Zika	virus	outbreak.	 It	highlights	 its	dependence	 on	 the	 method	 used	 for	 determining	 gestational	 age	 and	 other	anthropometric	 parameters,	 and	 includes	 original	 results	 of	 prevalence	 of	microcephaly	in	four	countries	from	two	different	continents	(Mozambique,	Brazil,	Guatemala	and	Colombia).	Alternative	definitions	of	microcephaly	are	proposed	in	order	to	allow	the	identification	of	true	cases	of	microcephaly	in	a	more	accurate	manner.	
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		The	epidemic	of	Zika	virus	(ZIKV)	is	steadily	spreading	in	the	Americas,	as	well	as	in	 some	 African	 and	 Asian	 countries.	 Although	 most	 infections	 seem	 to	 be	asymptomatic	 or	 with	 a	 mild	 clinical	 presentation,	 ZIKV	 infection	 during	pregnancy	has	been	associated	with	severe	fetal	outcomes,	including	microcephaly	(1).	The	WHO	has	recommended	reporting	the	prevalence	of	microcephaly	as	part	of	the	ZIKV	surveillance	in	countries	at	risk	or	with	ongoing	transmission.			Microcephaly	is	a	neurological	condition	in	which	the	head	circumference	(HC)	is	smaller	 than	 expected	 in	 a	 baby	 of	 the	 same	 gestational	 age	 (GA)	 and	 sex.	 It	 is	estimated	to	occur	in	1	per	6200-8500	births	and	it	may	be	associated	with	mental	retardation	(2).		Different	HC	cut-off	values	have	been	used	for	defining	microcephaly.	According	to	a	 recent	 WHO	 interim	 guidance	 update,	 microcephaly	 is	 recommended	 to	 be	defined	 as	 a	 HC	 below	 two	 Standard	 Deviations	 on	 the	 reference	 curves,	 as	measured	in	the	first	24	hours	of	life	(3).	For	full	term	newborns	(37-41	weeks),	it	is	suggested	to	use	the	WHO	growth	curves,	by	sex	(that	is,	a	cut	off	of	31.5	cm	and	31.9	cm	for	girls	and	boys	respectively)	(4).	Intergrowth-21	Size	at	Birth	Standards	(5)	 are	 preferred	 for	 premature	 and	 post	 term	 newborns	 or	 when	 accurate	gestational	age	is	known.	Currently,	international	recommendations	for	identifying	cases	 of	 microcephaly	 warn	 of	 the	 importance	 of	 accuracy	 in	 determining	gestational	age	and	proportionality	of	HC	to	body	size	(3),	which	are	two	issues	not	taken	 into	 account	 in	 the	 previous	 various	 definitions	 of	 microcephaly	 used.	
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However,	these	warnings	do	not	materialize	into	concrete	and	objective	measures	and,	 therefore,	 neonates	 that	 need	 special	management	 and	 follow-up	 should	be	identified	 only	 by	 the	 experience	 and	 subjectivity	 of	 the	 health	 professionals	providing	care	to	neonates	and	their	families.		Several	methods	can	be	used	 to	estimate	gestational	age,	such	as	 the	date	of	 last	menstrual	 period	 (LMP),	 ultrasound	 (US),	 or	 clinical	 assessment.	 Postnatal	examination	of	the	newborn	with	clinical	scoring	for	external	and/or	neurological	characteristics,	such	as	the	Dubowitz	test	(6)	or	Ballard	score	(7),	are	used	in	low-income	countries	where	LMP	estimates	are	usually	unreliable,	attendance	in	early	pregnancy	 for	 prenatal	 care	 is	 unusual	 and	 ultrasound	 examination	 is	 rarely	available.	The	agreement	between	these	methods	has	not	been	well	established.	It	has	 been	 observed	 that	 Dubowitz	 score	 underestimates	 GA	 in	 small-for	gestational-age	(SGA)	and	term	infants	(8).	In	addition,	Ballard	exam	misclassified	approximately	 80%	 of	 preterm	 infants	 as	 term	 when	 compared	 with	 the	 best	obstetric	estimate	combining	LMP	with	US,	suggesting	an	overestimation	of	GA	(9).			A	small	head	is	not	strictly	synonymous	with	microcephaly.	It	could	be	the	result	of	intrauterine	growth	retardation	as	it	happens	in	SGA	babies,	or	simply	be	due	to	a	genetic	 family	 condition	 (10).	 The	 disproportionality	 between	 the	 cranial	dimension	and	body	size	is	omitted	in	the	definition	of	microcephaly.	Few	studies	have	investigated	the	association	between	HC	and	other	anthropometric	measures,	such	as	weight	and	height,	with	widely	variable	and	even	conflicting	results	(11).	Cubed	 HC	 and	 body	 weight	 significantly	 correlate,	 giving	 an	 almost	 constant	average	 of	 10	 cm3/g	 and	 standard	 deviation	 of	 1,	 and	 this	 seems	 to	 be	 a	 useful	
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index	 to	 assess	 the	 proportion	 of	 head	 size	 to	 body	 mass	 at	 birth	 and	 during	infancy	(12).	The	measurement	of	this	index	could	contribute	to	early	diagnosis	of	diseases	such	as	hydrocephalus	or	microcephaly	(12).		To	 illustrate	 this	 discussion	 and	 provide	 baseline	 data	 for	 surveillance,	we	 have	calculated	 the	prevalence	of	microcephaly	 in	babies	born	 to	mothers	 enrolled	 in	two	different	pregnancy	 cohort	 studies	 among	Mozambican	women	 (13,	14,	15),	where	Dubowitz	and	Ballard	tests	were	used	to	determine	the	GA;	and	in	another	study	 carried	 out	 in	 three	 Latin	 American	 countries	 (Guatemala,	 Brazil	 and	Colombia)	(16),	in	which	the	Ballard	score	or	ultrasound	were	used.	Results	of	the	estimated	 prevalence	 of	 microcephaly	 in	 4730	 newborns	 of	 26-42	 weeks	 of	gestational	 age	 with	 complete	 information	 of	 anthropometric	 measurements	 at	birth	are	shown	in	Table	1.			The	prevalences	of	microcephaly	defined	according	to	WHO	guidelines	were	1.7%	and	 4.1%	 in	Mozambique;	 and	 8.2%,	 12.5%	 and	 15.2%	 in	 Brazil,	 Colombia	 and	Guatemala	 respectively	 (Table	 1).	 The	difference	 in	 prevalence	 between	 the	 two	studies	 in	Mozambique	could	be	explained	by	 the	different	methods	used	 for	GA	estimation.	Of	the	total	327	cases	of	microcephaly,	169	were	SGA	(52%)	and	they	had	a	mean	ratio	of	HC	relative	to	body	mass	of	12.2	cm3/g	[95%CI:	(11.9,	12.6)],	which	is	above	the	reference	average	of	10	cm3/g.	This	suggests	that	their	heads	were	 not	 smaller	 than	 expected	 for	 their	 body	 size,	 but	 they	were	 either	 babies	with	growth	retardation,	or	 there	was	an	overestimation	of	 their	GA.	 In	contrast,	the	corresponding	mean	ratio	among	newborns	with	microcephaly	who	were	not	SGA	was	 10.0	 cm3/g	 [95%CI:	 (9.8,	 10.2)],	which	means	 that	 some	 of	 them	may	
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truly	 have	 a	 smaller	 than	 expected	 head.	 Consequently,	 we	 calculated	 the	prevalence	 of	 microcephaly	 among	 babies	 not	 SGA	 (central	 column	 of	 Table	 1),	obtaining	a	much	lower	proportion	of	microcephaly.		The	values	obtained	with	this	definition	 should	 be	 closer	 to	 reality	 since	 it	 incorporates	 the	 concept	 of	disproportionality	of	HC	to	body	size	taking	into	account	whether	the	newborn	is	SGA	 or	 not.	 This	 is	 one	 explicit	 recommendation	 of	 the	WHO	 guidelines,	 but	 no	objective	measure	is	proposed	for	it,	and	SGA	could	be	one	of	them.	However,	this	definition	does	not	allow	to	identify	microcephaly	among	SGA	newborns.	Thus,	in	order	 to	 assess	 the	 prevalence	 of	 microcephaly	 including	 those	 with	 SGA,	 we	propose	an	alternative	definition	(third	column	of	Table	1)	that	takes	into	account	the	 ratio	 of	HC	 to	 body	weight.	 The	main	 advantage	 of	 using	 this	 ratio	 is	 that	 it	does	 not	 depend	 on	 the	 method	 used	 for	 GA	 assessment,	 all	 of	 which	 have	important	limitations	in	low	and	middle-income	settings.	Thus,	it	could	widely	be	used	 in	 these	 settings	 for	 individual	 case	 management	 and	 microcephaly	surveillance	in	a	more	accurate	manner.		
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Table	1.	Prevalence	of	Microcephaly	and	95%	Confidence	Interval	at	different	sites	and	methods	for	GA	assessment	
	
Site	 Gestational	age	(a)		 Microcephaly	(b)		 Microcephaly
	(b)		 Microcephaly	(b)		
&	not	SGA	(c)		 &	disproportionality	(d)		
Mozambique	(e)		
Prematures	 5/41	[12.2%;	(4.1,	26.2)]	 0/41	[0.0%;	(0.0,	8.6)]	 0/41	[0.0%;	(0.0,	8.6)]	
Full	term	 10/795	[1.3%;	(0.6,	2.3)]	 0/795	[0.0%;	(0.0,	0.5)]	 1/795	[0.1%;	(0.0,	0.7)]	
Post	term	 1/104	[1.0%;	(0.0,	5.2)]	 0/104	[0.0%;	(0.0,	3.5)]	 0/104	[0.0%;	(0.0,	3.5)]	
Overall	 16/940	[1.7%;	(1.0,	2.7)]	 0/940	[0.0%;	(0.0,	0.4)]	 1/940	[0.1%;	(0.0,	0.6)]	
Mozambique	(f)		
Prematures	 11/165	[6.7%;	(3.4,	11.6)]	 3/165	[1.8%;	(0.4,	5.2)]	 0/165	[0.0%;	(0.0,	2.2)]	
Full	term	 65/1680	[3.9%;	(3.0,	4.9)]	 38/1680	[2.3%;	(1.6,	3.1)]	 15/1680	[0.9%;	(0.5,	1.5)]	
Post	term	 0/26	[0.0%;	(0.0,	13.2)]	 0/26	[0.0%;	(0.0,	13.2)]	 0/26	[0.0%;	(0.0,	13.2)]	
Overall	 76/1871	[4.1%;	(3.2,	5.1)]	 41/1871	[2.2%;	(1.6,	3.0)]	 15/1871	[0.8%;	(0.4,	1.3)]	
Brazil	(f)		
Prematures	 5/27	[18.5%;	(6.3,	38.1)]	 2/27	[7.4%;	(0.9,	24.3)]	 0/27	[0.0%;	(0.0,	12.8)]	
Full	term	 52/653	[8.0%;	(6.0,	10.3)]	 27/653	[4.1%;	(2.7,	6.0)]	 17/653	[2.6%;	(1.5,	4.1)]	
Post	term	 2/37	[5.4%;	(0.7,	18.2)]	 2/37	[5.4%;	(0.7,	18.2)]	 2/37	[5.4%;	(0.7,	18.2)]	
Overall	 59/717	[8.2%;	(6.3,	10.5)]	 31/717	[4.3%;	(3.0,	6.1)]	 19/717	[2.6%;	(1.6,	4.1)]	
Colombia	(g)		
Prematures	 1/33	[3.0%;	(0.1,	15.8)]	 0/33	[0.0%;	(0.0,	10.6)]	 0/33	[0.0%;	(0.0,	10.6)]	
Full	term	 23/187	[12.3%;	(8.0,	17.9)]	 19/187	[10.2%;	(6.2,	15.4)]	 10/187	[5.3%;	(2.6,	9.6)]	
Post	term	 8/35	[22.9%;	(10.4,	40.1)]	 6/35	[17.1%;	(6.6,	33.6)]	 7/35	[20.0%;	(8.4,	36.9)]	
Overall	 32/255	[12.5%;	(8.7,	17.3)]	 25/255	[9.8%;	(6.4,	14.1)]	 17/255	[6.7%;	(3.9,	10.5)]	
Guatemala	(f)		
Prematures	 2/42	[4.8%;	(0.6,	16.2)]	 2/42	[4.8%;	(0.6,	16.2)]	 1/42	[2.4%;	(0.1,	12.6)]	
Full	term	 48/592	[8.1%;	(6.0,	10.6)]	 29/592	[4.9%;	(3.3,	7.0)]	 14/592	[2.4%;	(1.3,	3.9)]	
Post	term	 94/313	[30.0%;	(25.0,	35.4)]	 30/313	[9.6%;	(6.6,	13.4)]	 20/313	[6.4%;	(3.9,	9.7)]	
Overall	 144/947	[15.2%;	(13.0,	17.7)]	 61/947	[6.4%;	(5.0,	8.2)]	 35/947	[3.7%;	(2.6,	5.1)]	
	
	(a):	Prematures	(born	before	37	weeks	of	pregnancy),	full	term	(37	to	41	weeks),	or	post	term	(more	than	41	weeks	of	pregnancy)	(b):	Defined	according	to	the	WHO	Child	Growth	Standards	for	full	term	neonates	from	Mozambique,	Brazil	and	Guatemala	(not	accurate	gestational	age);	Intergrowth-21	Size	at	Birth	Standards	were	used	for	full	term	neonates	from	Colombia	(gestational	age	determined	by	US)	and	for	all	prematures	and	post	term	neonates	(c):	Defined	as	having	a	birth	weight	less	than	the	10th	percentile	for	the	gestational	age	according	the	Intergrowth-21	Size	at	Birth	Standards	(d):(HC(cm)3/Body	weight(g))	<	10	(e):	Gestational	age	by	Dubowitz	test	(f):	Gestational	age	by	Ballard	score	(g):	Gestational	age	by	Ultrasound	
